Sinopharm Group Co. Ltd. — Earnings Release 2023

Oct 26, 2023

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

==> picture [468 x 223] intentionally omitted <==

ANNOUNCEMENT PRINCIPAL UNAUDITED ACCOUNTING DATA AND FINANCIAL INDICATORS OF SINOPHARM ACCORD FOR THE THIRD QUARTER ENDED 30 SEPTEMBER 2023

This announcement is made pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

Reference is made to the overseas regulatory announcement of Sinopharm Group Co. Ltd. (the “ Company ”) dated 26 October 2023 (the “ Announcement ”) in relation to the report for the third quarter ended 30 September 2023 of China National Accord Medicines Corporation Ltd. (“ Sinopharm Accord ”), a subsidiary of the Company and whose A shares and B shares are listed on the Shenzhen Stock Exchange (stock code for A shares: 000028; stock code for B shares: 200028).

The board of directors of the Company would like to draw the attention of its shareholders and the public investors to the following principal unaudited accounting data and financial indicators of Sinopharm Accord for the third quarter ended 30 June 2023 as set out in the Announcement.

* The Company is registered as a non-Hong Kong company under the Hong Kong Companies Ordinance under its Chinese name and the English name “Sinopharm Group Co. Ltd.”.

PRINCIPAL UNAUDITED ACCOUNTING DATA AND FINANCIAL INDICATORS OF SINOPHARM ACCORD

Whether it has retroactive adjustment or restatement on previous accounting data or not √ Yes □ No

Reasons for retroactive adjustment or restatement Other reasons

ther reasons
				Unit: Yuan
				Currency: RMB
				Changes of this
	The Reporting	Same period of last year		period over the same period of
	Period			last year
		Before	After	After
		adjustment	adjustment	adjustment
Revenue	18,198,332,914.41	18,487,856,446.74	18,487,856,446.74	-1.57%
Net profit attributable
to shareholders of the
listed company	359,412,549.43	373,428,199.20	373,428,199.20	-3.75%
Net profit attributable
to shareholders of the
listed company after
deducting non-
recurring gains and
losses	348,175,150.29	355,431,872.47	355,431,872.47	-2.04%
Net cash flow arising
from operating
activities	—	—	—	—
Basic earnings per
share (Yuan/Share)	0.65	0.87	0.67	-2.99%
Diluted earnings per
share (Yuan/Share)	0.65	0.87	0.67	-2.99%
				Decreased by
Weighted average				0.26 percentage
return on net assets	2.14%	2.40%	2.40%	point

				Changes of the
				period from
				the beginning
	From the			of the year to
	beginning of the	Same period	of last year	the end of the
	year to the end of			Reporting
	the Reporting			Period over the
	Period			same period of
				last year(%)
		Before	After	After
		adjustment	adjustment	adjustment
Revenue	56,585,864,462.43	54,616,766,496.72	54,616,766,496.72	3.61%
Net profit attributable
to shareholders of the
listed company	1,189,663,637.63	1,047,644,112.13	1,047,644,112.13	13.56%
Net profit attributable
to shareholders of the
listed company after
deducting non-
recurring gains and
losses	1,142,821,421.51	1,008,289,175.23	1,008,289,175.23	13.34%
Net cash flow arising
from operating
activities	1,465,469,101.73	2,057,795,818.15	2,057,795,818.15	-28.78%
Basic earnings per
share (Yuan/Share)	2.14	2.45	1.88	13.83%
Diluted earnings per
share (Yuan/Share)	2.14	2.45	1.88	13.83%
				Increased by
Weighted average				0.34 percentage
return on net assets	7.18%	6.84%	6.84%	point
				Changes of this
	At the end of the Reporting Period	At the end of last year Before adjustment After adjustment		period-end over the end of last year After adjustment
Total assets	50,736,934,574.27	42,615,760,577.42	42,615,760,577.42	19.06%
Net assets attributable
to shareholders of
listed company	16,972,948,050.25	16,125,890,447.68	16,125,890,447.68	5.25%

Note: The Reporting Period refers to the three months ended 30 September 2023.

INFORMATION OF THE OPERATION RESULTS AND FINANCIAL SITUATION

From January to September of 2023, Sinopharm Accord has focused on the goal of sustainable and high-quality development, undertaken various measures simultaneously and achieved an overall increase in operating efficiency. Sinopharm Accord has achieved a revenue of RMB56.586 billion, representing a year-on-year increase of 3.61%; an operating profit of RMB1.823 billion, representing a year-on-year increase of 16.54%; a total profit of RMB1.820 billion, representing a year-on-year increase of 16.00%; a net profit attributable to shareholders of the listed company of RMB1.190 billion, representing a year-on-year increase of 13.56%. As a result, the basic earnings per share increased by 13.83% and the weighted average return on net assets increased by 0.34 percentage point.

From January to September 2023, the distribution segment of Sinopharm Accord has achieved a revenue of RMB39.569 billion, representing a year-on-year increase of 2.43%, and a net profit of RMB788 million, representing a year-on-year decrease of 0.57%. The retail segment has achieved a revenue of RMB17.722 billion, representing a year-on-year increase of 6.37%, and a net profit of RMB378 million, representing a year-on-year increase of 80.27%,.

By order of the Board Sinopharm Group Co. Ltd. Yu Qingming Chairman

Shanghai, the PRC 26 October 2023

As at the date of this announcement, the executive directors of the Company are Mr. Yu Qingming and Mr. Liu Yong; the non-executive directors of the Company are Mr. Chen Qiyu, Mr. Hu Jianwei, Mr. Deng Jindong, Mr. Wang Kan, Mr. Wang Peng, Mr. Wen Deyong, Mr. Li Dongjiu and Ms. Feng Rongli; and the independent non-executive directors of the Company are Mr. Chen Fangruo, Mr. Li Peiyu, Mr. Wu Tak Lung, Mr. Yu Weifeng and Mr. Shi Shenghao.